IDEX Corp (IEX) (Q3 2026) Earnings Call Highlights: Record Sales and EPS, Raised

IDEX Corp (IEX) reported record sales and EPS for Q3 2026, raising full-year guidance. The company faces inflation and energy price challenges but offsets costs through pricing and productivity. Chemical valves and agriculture businesses saw year-over-year declines, while life sciences remained flat. Data center orders are unpredictable. Q4 margins are expected to decline due to fewer production days and maintenance.

Original reporting
Published Oct 30, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IDEX Corp (IEX) (Q3 2026) Earnings Call Highlights: Record Sales and EPS, Raised — source image
Decision brief

The 30-second read

$IEXNeutralMed
01

Why it matters

Guidance suggests modest pricing benefits but margin compression, implying limited near‑term upside for the stock.

02

Market read

The call offers new guidance that may influence IDEX's stock and related industrial peers.

03

What to watch

Potential upside from new water‑tech platform and AI applications could improve future growth.

Relevance 6/10Novelty 6/10Timing: today

Background

IDEX Corp held its Q3 2026 earnings call, providing qualitative updates on pricing, margins, and segment performance.

Company-level read

Ticker impact

$IEXNeutralMedium confidence
Context

CEO said pricing contributes around 2% to top line in 2026 and gross leverage is 1.8x.

Expected impact

potential slight downside as margin pressure may outweigh pricing benefit

Evidence & confidence

The 2% pricing contribution is modest while margins are expected to compress, suggesting limited bullish pressure.

Market effects

Industrial and life‑sciences segments may see mixed performance, with pricing tailwinds offset by margin pressure.

U.S. industrial stocks could experience modest pressure following IDEX guidance.

Limited, as the guidance pertains mainly to IDEX's niche markets.

Counterpoint

Investors might view the pricing tailwind as a catalyst for upside despite margin concerns.

Key entities

  • IDEX Corp

    Industrial solutions provider discussing Q3 2026 outlook.

Related articles

$IEXHighAI 8/10

DA Davidson raises IDEX stock price target to $245 on strength

DA Davidson raised its price target on IDEX Corp (NYSE:IEX) to $245 from $240, citing strength in its Health & Science Technologies and Fire & Safety segments. The stock has risen 39% over the past year. IDEX reported Q3 2026 earnings of $2.33 per share, beating estimates, with revenue of $952 million. The company also raised its full-year guidance.

$IEXMedAI 8/10

Idex: Q3 Earnings Snapshot

IDEX Corp. (IEX) reported Q3 net income of $144.1M, or $1.95 per share, exceeding analyst estimates. Adjusted EPS was $2.33. Revenue was $951.7M, also beating forecasts. The company raised its full-year EPS guidance to $8.91-$8.96 per share.

$IEXHighAI 8/10

IDEX (IEX) Q3 2026 Earnings Call Transcript

IDEX (IEX) reported Q3 2026 net sales of $952M, up 8%, and adjusted EPS of $2.33, up 15%. Organic orders reached $991M, growing 13%. HST, FMT, and FSDP segments showed growth. Full-year guidance raised: organic growth 6.5-6.8%, adjusted EPS $8.91-$8.96. Inflation and chemical sector weakness noted as risks.

$IEXHighAI 8/10

IDEX Q3 2026 slides: advantaged markets drive beat, guidance raised

IDEX Corporation (NYSE:IEX) reported Q3 2026 earnings with 8% organic sales growth and 15% increase in adjusted EPS, driven by 'advantaged markets'. Sales reached $952M, adjusted EBITDA margin expanded to 27.8%, and free cash flow grew 14%. The company raised its full-year outlook, with shares up 0.92% to $235.35. HST segment led growth with 13% organic sales growth.

$IEXMedAI 8/10

IDEX (NYSE:IEX) beats Q3 2026 sales expectations

IDEX reported Q3 2026 revenue of $951.7 million, beating estimates by 1.8%. Adjusted EPS was $2.33, a 4% beat. Adjusted EBITDA reached $264.8 million, a 3.2% beat. Management raised full-year adjusted EPS guidance to $8.94. Operating margin remained steady at 21.9%, while free cash flow margin improved to 22.5%.